First pediatric patients dosed in phase 3 Dextenza trial

Ocular Therapeutix has dosed the first patients in a phase 3 clinical trial of Dextenza for postoperative ocular inflammation and pain in children after cataract surgery, according to a press release.
The U.S.-based, randomized, multicenter trial will enroll about 60 patients between 0 and 3 years old and evaluate the safety and biological activity of Dextenza (dexamethasone ophthalmic insert 0.4 mg) against prednisolone acetate suspension eye drops.
“Performing cataract surgery in children represents a different set of surgical and technical challenges. One area critical to surgical

Full Story →